Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Drug May Benefit Head, Neck Cancer Patients

April 8, 2014 8:30 am | News | Comments

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) may benefit from treatment with the investigational drug dacomitinib if their cancer has no defects in a cell signaling pathway called the PI3K pathway and no signs of excessive inflammation. Read more...

TOPICS:

Gilead Hep C Combo Gets Breakthrough Therapy Status, Priority Review from FDA

April 7, 2014 2:21 pm | News | Comments

Gilead Sciences Inc. announced that the FDA has granted priority review and a Breakthrough Therapy designation to the comapny's fixed-dose combination of ledipasvir and sofosbuvir for the treatment of chronic hepatitis C genotype 1. Read more...

TOPICS:

Ambit Initiates Phase 2 Trial of Quizartinib Combo in AML, MDS

April 7, 2014 2:14 pm | News | Comments

Ambit Biosciences announced the initiation of the Phase 2 cohort of a Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia patients, or FLT3-ITD positive AML patients in first relapse. Read more...

TOPICS:
Advertisement

FDA Approves Pradaxa for DVT, Pulmonary Embolism

April 7, 2014 2:09 pm | News | Comments

Boehringer Ingelheim announced that the FDA has approved Pradaxa for the treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. Read more...

TOPICS:

Antibody-Drug Conjugate Benefits Melanoma Patients in Phase 1

April 7, 2014 2:00 pm | News | Comments

The investigational drug DEDN6525A, which is a new member of a class of drugs called antibody-drug conjugates, was safe, tolerable, and showed hints of activity against three different forms of melanoma. Read more...          

TOPICS:

New Lilly Drug Promising Against Metastatic Breast Cancer

April 7, 2014 1:48 pm | News | Comments

The new oral drug LY2835219, an inhibitor of cyclin-dependent kinases 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer, particularly for those with hormone receptor-positive disease. Read more...     

TOPICS:

Novartis Men B Vaccine Gets Breakthrough Designation from FDA

April 7, 2014 1:38 pm | News | Comments

Novartis announced that Bexsero (Meningococcal Group B Vaccine) has received a Breakthrough Therapy designation-the fourth such designation for Novartis-from the FDA. Read more...       

TOPICS:

CRT, Teva Collaboration IDs New Cancer Drug Candidate

April 7, 2014 10:41 am | News | Comments

Cancer Research Technology announced a successful outcome to their existing collaboration with Teva through the identification of a novel atypical Protein Kinase C (aPKC) inhibitor pre-clinical candidate, licensed by Teva. Read more...     

TOPICS:
Advertisement

Roche Buys Orphan Drug Molecule from Oryzon

April 7, 2014 10:35 am | News | Comments

Roche and Oryzon Genomics SA announced they have entered into a worldwide collaboration to research, develop and commercialize inhibitors of Lysine Specific Demethylase-1, an epigenetic modulator that regulates gene expression. Read more...   

TOPICS:

Pfizer's New Breast Cancer Drug Shows Promise

April 7, 2014 8:30 am | by Christopher S. Rugaber, AP Economics Writer | News | Comments

An experimental drug has shown encouraging results in treating advanced breast cancer in an early clinical trial, pharmaceutical giant Pfizer reported Sunday. The drug prevented breast cancer from worsening for 20.2 months in trial. Read more...

TOPICS:

Meda Turns Down Mylan's Merger Proposal

April 7, 2014 8:30 am | News | Comments

Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses. Meda AB says talks between the two companies have stopped "without further actions." Read more...       

TOPICS:

Daiichi Sankyo Selling Ranbaxy to Sun Pharmaceutical

April 7, 2014 8:25 am | News | Comments

Daiichi Sankyo Co. said Monday it will sell its stake in Indian unit Ranbaxy Laboratories Ltd. to Sun Pharmaceutical Industries Ltd., as the Japanese firm shifts its generic drug business strategy. Read more...           

TOPICS:

Mallinckrodt to Buy Questcor for $5.2B

April 7, 2014 8:17 am | News | Comments

Ireland's Mallinckrodt is buying Questcor Pharmaceuticals Inc. for a combination of stock and cash valued at about $5.2 billion, a purchase that will help to diversify Mallinckrodt's business. Read more...         

TOPICS:

Plant Nanotubes May Improve Chemotherapy Treatment

April 4, 2014 1:52 pm | News | Comments

Researchers took what some would consider garbage and made a remarkable scientific tool, one that could someday help to correct genetic disorders or treat cancer without chemotherapy’s nasty side effects. Read more...         

TOPICS:

Sanaria Malaria Vaccine Wins Excellence Award

April 4, 2014 1:40 pm | News | Comments

Sanaria received the 2014 Vaccine Industry Excellence Award for the "Best Prophylactic Vaccine" at a ceremony held last month in Washington, D.C. during the 14th World Vaccine Congress. Read more...                 

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading